Fingerprint
Dive into the research topics of 'Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically